Member Info for Aether

Tattyhead

A T/O is the best way of getting this to market. Synairgen don't have the expertise or political clout. That is obvious now.

How much is it worth if the data is good?

Four green boxes.

Bin it. Don't feed it.

A T/O or JV are possible if the data is good.

POLYGON are not going to allow business as usual at SNG.

They will want to extract as much money as possible while the company is still solvent.

They won't want to hold for clinical trials or rights issues.

MrCosts - If the Deep Dive data shows statistical significance for some sub-groups and the Long Covid data is good do you think the sp will rerate?

Can you translate it, M!

It's a long wait until May.

The BoD had better deliver the goods. They have had long enough.

A peaceful sea of green :D

Green bin it.

Don't feed it.

When you piece together all posts it's obviously mentally ill.

Green bin it.

Don't feed it's insanity.

Good points, Manifesto.

I still think EUA is unlikely but good data will rerate the sp AND increase the likelihood of a T/O.

Prion25

Blood samples weren't taken in Sprinter 3 BUT they were taken for Activ-2 P2.

The vaccines suppress the production of innate interferons therefore additional interferons are needed to help fight the infection?

This could be useful for SNG.

"Suppression of type I interferon responses results in impaired innate immunity."

WOW.

If this is true, could SNG help here?

A T/O is the most realistic way to extricate from this share.

The product is good but needs a larger pharmaceutical company with expertise and political clout to bring it to market.

Messing P3 and not explaining anything is shocking.

Polygon is the insurance policy that will focus the BoD. They will want out as soon as possible with the most value.

How much would this be worth in a T/O given SNG001's safety profile, agnostic potency, ease of delivery, combined with good deep dive data, Activ-2 P2 data, long covid data and possible statistical significance in sub-categories?

Activ-2 data soon as well.

I suspect Polygon will be critical in ensuring SNG are on point going forward.

I hope they are putting out feelers to larger pharmaceutical companies to see if they are interested and at what price.

Again, a T/O is the best way to extricate ourselves from this share.

£1 break even.

Green boxes are relaxing :D

I feel your pain and rage.

The question is can it be salvaged?

The product is good and can save MANY lives if taken to market.

Another more experienced company is needed with the experience and clout to bring it to market.

What will Polygon do other than protect its position by preventing a low ball TO?

They're smart they must know the BoD need help.

Also, how long would a new clinical trial last?

It will be done and dusted quicker than a couple of years.

Polygon will want out as quickly as possible. They will NOT want to wait "a couple of years".

If there are gems in the deep dive Sprinter 3, Activ-2 P2, and deep dive data, a Big Pharma will be keen to buy before it gets too expensive.

That is the usual way Big Pharma stock up on products:

They usually buy after a successful P2.

Also, NIH are keeping us in the Activ trial and are even re-writing the protocol and choosing a trial.

A T/O to break even at £1.

It's serious mental illness. It's not paid derampers.

What would be the length of any clinical trials?